Daojing Wang, Ph.D., Founder and CEO
Dr. Wang founded Newomics Inc. in August 2011 while a Career Scientist and Principal Investigator at Lawrence Berkeley National Laboratory (LBNL), where he had worked since 2002. Dr. Wang launched Newomics in September 2013 to further its technology development and commercialization. Dr. Wang has been continuously serving as a principal investigator for multiple research grants from NIH, DOE, NASA, and CBCRP. He has published extensively in highly respected journals such as Aging Cell, Analytical Chemistry, Cancer Research, Journal of Proteome Research, Molecular and Cellular Proteomics, Proceedings of the National Academy of Sciences, Proteomics, and Trends in Biotechnology etc. Dr. Wang is the co-inventor of multiple issued and pending patents including M3 emitters, MEA chips, and senescence chips, which together lay the foundation for Newomics’ platforms and solutions for precision medicine. Prior to joining LBNL, Dr. Wang had performed research at SurroMed Inc. and the University of California, San Francisco. Dr. Wang obtained his B.S. degree from University of Science and Technology of China (USTC) in 1994, Ph.D. in Chemistry from Princeton University in 1999, and completed his postdoctoral training at the University of California, Berkeley in 2000.
Gurmil Gendeh, Ph.D., VP of Commercialization
Dr. Gendeh has 20 years of commercialization experience of innovative technologies and solutions to the life science and pharmaceutical markets. He started his career at Amersham Biosciences, now part of GE Healthcare, as an Application Scientist for Genomics and Proteomics, and later as Business Development Manager for Mass Spectrometry in North America. After GE, he spent 7 years at Dionex Corporation as Global Market Development Manager for Life Science and Biopharma markets where he helped Dionex achieve double-digit worldwide sales growth for Biopharma segment. Dionex was acquired by Thermo Fisher Scientific in 2011. Dr. Gendeh joined Agilent Technologies in a leadership role in 2013 as the Director of Biopharmaceutical Segment Marketing. There, he hired, coached and built a team of Biopharma Market Managers that developed, implemented and monitored worldwide go-to-market plans and consistently delivered double-digit market growths. Prior to joining Newomics, he was at Shimadzu Scientific Instruments as Pharmaceuticals Marketing Leader. Dr. Gendeh obtained his Ph.D. in Biochemistry and Molecular Biology from the National University of Singapore. He did his postdoctoral work in Cancer Biology at the Stanford University in Palo Alto.
Pan Mao, Ph.D., Co-Founder
Dr. Mao co-founded Newomics Inc. with Dr. Wang in August 2011. Dr. Mao is the co-inventor of M3 emitters and MEA chips. Dr. Mao has extensive experience in developing micro/nanofluidic technologies to solve biological problems. He has made significant contributions to the application of micro/nanofluidics for biological sample preparation and development of fully integrated micro/nanofluidic bioanalytical systems to perform high-throughput omics analysis. Dr. Mao has published over 15 papers in well-respected journals such as Analytical Chemistry, Journal of Proteome Research, and Lab-on-a-Chip, and has served as principal investigator and co-investigator at Newomics Inc. for several NIH SBIR projects. Dr. Mao obtained his B.S. degree from USTC in 2002, Ph.D. in Mechanical Engineering from MIT in 2009, and completed his postdoctoral training at LBNL in 2013.